Test can personalise use of immunotherapy and chemotherapy for head and neck cancer 25 Mar 2022 Matching cancer patients to treatment based on their levels of a key immune protein may allow doctors to select those who would benefit most from the combination of immunotherapy and chemotherapy, researchers report. Find out more Show/Hide
ICR researchers named among world’s most influential scientists 19 Nov 2021 Six researchers at the ICR and The Royal Marsden have been named in a list of the world's most influential by the by science analytics company Clarivate. Find out more Show/Hide
Immunotherapy combination could be alternative to ‘Extreme’ chemotherapy in some head and neck cancers 11 Oct 2021 An immunotherapy combination could be better than standard ‘Extreme’ chemotherapy as first-line treatment for some patients with relapsed or metastatic head and neck cancer, or both, a major phase III trial suggests. Find out more Show/Hide
ICR welcomes approval of immunotherapy for head and neck cancer in Scotland but warns of ‘home nations lottery’ 07 Sep 2020
The ICR responds to decision by NICE not to recommend pembrolizumab as first-line treatment for advanced head and neck cancer 15 Jan 2020
Major trial backs immunotherapy as standard first-line treatment for head and neck cancer 23 Nov 2019